In a small case series of non-small-cell lung cancer patients with monoclonal concomitant EGFR and ALK alterations, ALK inhibitors appeared to be effective for patients with co-alterations [7], but our patient eventually progressed while on lorlatinib. The gene discussed is ALK; the disease is non-small cell lung carcinoma.